Senotherapeutics for healthy ageing
Nature Reviews Drug Discovery 17, 377 (2018).
doi:10.1038/nrd.2018.44
Authors: Laura J. Niedernhofer & Paul D. Robbins
The recent manuscript by Childs et al. in Nature Reviews Drug Discovery thoroughly reviewed the important role senescent cells play in driving ageing and age-related diseases. The review also highlighted the clinical importance of developing senotherapeutic approaches to selectively kill senescent cells (senolytics) (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - April 13, 2018 Category: Drugs & Pharmacology Authors: Laura J. Niedernhofer Paul D. Robbins Tags: Correspondence Source Type: research
Chemical probes and drug leads from advances in synthetic planning and methodology
Nature Reviews Drug Discovery 17, 333 (2018).
doi:10.1038/nrd.2018.53
Authors: Christopher J. Gerry & Stuart L. Schreiber
Screening of small-molecule libraries is a productive method for identifying both chemical probes of disease-related targets and potential starting points for drug discovery. In this article, we focus on strategies such as diversity-oriented synthesis that aim to explore novel areas of chemical space efficiently by (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - April 13, 2018 Category: Drugs & Pharmacology Authors: Christopher J. Gerry Stuart L. Schreiber Tags: Review Source Type: research
The gastroesophageal cancer drug market
Nature Reviews Drug Discovery 17, 311 (2018).
doi:10.1038/nrd.2018.35
Authors: Paul Wilcock & Rachel M. Webster
Immune checkpoint inhibitors are forecast to expand the market for gastroesophageal cancer drugs, which is particularly large in Asia. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - April 3, 2018 Category: Drugs & Pharmacology Authors: Paul Wilcock Rachel M. Webster Tags: News and Analysis Source Type: research
Infectious disease: Virus-based tuberculosis vaccine
Nature Reviews Drug Discovery 17, 242 (2018).
doi:10.1038/nrd.2018.50
Author: Sarah Crunkhorn
The bacille Calmette–Guérin vaccine can protect children from tuberculosis (TB), but is not effective in adults, probably owing to Mycobacterium tuberculosis (Mtb) manipulating human innate immune responses to enable persistent infection. A recent study reports a promising alternative vaccine approach — the use of (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - March 28, 2018 Category: Drugs & Pharmacology Authors: Sarah Crunkhorn Tags: Research Highlight Source Type: research
Sepsis: Gut bacteria induce protective IgA
Nature Reviews Drug Discovery 17, 242 (2018).
doi:10.1038/nrd.2018.49
Author: Sarah Crunkhorn
The mechanisms mediating serum immunoglobulin A (IgA) responses and their potential role in protective immunity remain unknown. Wilmore and colleagues show that members of the Proteobacteria phylum in the gut of mice promote a T cell-dependent increase in serum IgA and IgA-secreting bone marrow plasma (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - March 28, 2018 Category: Drugs & Pharmacology Authors: Sarah Crunkhorn Tags: Research Highlight Source Type: research
Immunotherapy: iPSC-based cancer vaccine
Nature Reviews Drug Discovery 17, 242 (2018).
doi:10.1038/nrd.2018.48
Author: Sarah Crunkhorn
Pluripotent cells share antigens with cancer cells, suggesting that they could be used to prime the immune system to target cancer. Here, Kooreman and colleagues report the development of a vaccine based on irradiated mouse induced pluripotent stem cells. Prophylactically, the vaccine inhibited tumour growth (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - March 28, 2018 Category: Drugs & Pharmacology Authors: Sarah Crunkhorn Tags: Research Highlight Source Type: research
Antivirals: Topical therapy for ocular herpes
Nature Reviews Drug Discovery 17, 242 (2018).
doi:10.1038/nrd.2018.47
Author: Sarah Crunkhorn
Nucleoside analogue-based drugs control herpes simplex virus type 1 (HSV-1) infection of the eye, but are limited by potential drug resistance and adverse effects. Jaishankar and colleagues report that the small-molecule TANK-binding kinase 1 (TBK1) inhibitor, BX795, suppresses HSV-1 infection in transformed and primary human (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - March 28, 2018 Category: Drugs & Pharmacology Authors: Sarah Crunkhorn Tags: Research Highlight Source Type: research
Drug delivery: DNA nanorobots — seek and destroy
Nature Reviews Drug Discovery 17, 242 (2018).
doi:10.1038/nrd.2018.40
Author: Conor A. Bradley
Due to the potential of DNA molecules as substrates for the production of molecular machines with biological functionality, there is much interest in using DNA-based nanorobotic systems for the targeted delivery of therapeutic payloads to tumours. A new study reports the development of autonomous 'DNA (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - March 28, 2018 Category: Drugs & Pharmacology Authors: Conor A. Bradley Tags: Research Highlight Source Type: research
Neurodevelopmental disorders: CRISPR to the rescue
Nature Reviews Drug Discovery 17, 240 (2018).
doi:10.1038/nrd.2018.39
Author: M. Teresa Villanueva
Fragile X syndrome (FXS) is a neurodevelopmental disorder caused by a CGG repeat expansion in the promoter region of FMR1. This mutation results in hypermethylation and silencing of FMR1 and absence, or reduction, of its gene product, fragile X mental retardation protein 1 (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - March 28, 2018 Category: Drugs & Pharmacology Authors: M. Teresa Villanueva Tags: Research Highlight Source Type: research
George Yancopoulos
Nature Reviews Drug Discovery 17, 234 (2018).
doi:10.1038/nrd.2018.41
When Leonard Schleifer recruited George Yancopoulos as CSO of Regeneron in 1988, Schleifer was running the company out of a one-bedroom apartment in New York City. Thirty years on, the company has brought six drugs to the US market, and has a pipeline of more than fifteen antibody therapies in development across cardiovascular disease, infectious disease, inflammation, immunology, oncology and more. Yancopoulos credits this success to stable management, a commitment to in-house science, end-to-end drug discovery and development capabilities, and ...
Source: Nature Reviews Drug Discovery - March 28, 2018 Category: Drugs & Pharmacology Tags: News and Analysis Source Type: research
Market watch: Upcoming market catalysts in Q2 2018
Nature Reviews Drug Discovery 17, 233 (2018).
doi:10.1038/nrd.2018.43
Author: Alexandra Heller
Potential market catalysts in the second quarter of 2018 include top-line clinical trial results for NEOD001 (developed by Prothena) for light-chain (AL) amyloidosis and ALXN1210 (developed by Alexion) for paroxysmal nocturnal haemoglobinuria (PNH), as well as an FDA advisory committee meeting on volanesorsen (developed by (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - March 28, 2018 Category: Drugs & Pharmacology Authors: Alexandra Heller Tags: News and Analysis Source Type: research
Market watch: Top drugs and companies by sales in 2017
Nature Reviews Drug Discovery 17, 232 (2018).
doi:10.1038/nrd.2018.42
Author: Lisa Urquhart
A look at the best-selling drugs in 2017 shows the top spots dominated by monoclonal antibodies which, despite their age and looming competition, are still pulling in billions of dollars (Fig. 1a). The success of these huge franchises is partly down to the (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - March 28, 2018 Category: Drugs & Pharmacology Authors: Lisa Urquhart Tags: News and Analysis Source Type: research
Unexplored therapeutic opportunities in the human genome
Nature Reviews Drug Discovery 17, 377 (2018).
doi:10.1038/nrd.2018.52
Author: Tudor I. Oprea, Cristian G. Bologa, Søren Brunak, Allen Campbell, Gregory N. Gan, Anna Gaulton, Shawn M. Gomez, Rajarshi Guha, Anne Hersey, Jayme Holmes, Ajit Jadhav, Lars Juhl Jensen, Gary L. Johnson, Anneli Karlson, Andrew R. Leach, Avi Ma'ayan, Anna Malovannaya, Subramani Mani, Steven L. Mathias, Michael T. McManus, Terrence F. Meehan, Christian von Mering, Daniel Muthas, Dac-Trung Nguyen, John P. Overington, George Papadatos, Jun Qin, Christian Reich, Bryan L. Roth, Stephan C. Schürer, Anton Simeonov, Larry A. Sklar, Noel So...
Source: Nature Reviews Drug Discovery - March 23, 2018 Category: Drugs & Pharmacology Authors: Tudor I. Oprea Cristian G. Bologa S ø ren Brunak Allen Campbell Gregory N. Gan Anna Gaulton Shawn M. Gomez Rajarshi Guha Anne Hersey Jayme Holmes Ajit Jadhav Lars Juhl Jensen Gary L. Johnson Anneli Karlson Andrew R. Leach Avi Ma'ayan Anna Malovannaya Sub Tags: Corrigendum Source Type: research
Unexplored therapeutic opportunities in the human genome
Nature Reviews Drug Discovery 17, 317 (2018).
doi:10.1038/nrd.2018.14
Authors: Tudor I. Oprea, Cristian G. Bologa, Søren Brunak, Allen Campbell, Gregory N. Gan, Anna Gaulton, Shawn M. Gomez, Rajarshi Guha, Anne Hersey, Jayme Holmes, Ajit Jadhav, Lars Juhl Jensen, Gary L. Johnson, Anneli Karlson, Andrew R. Leach, Avi Ma'ayan, Anna Malovannaya, Subramani Mani, Stephen L. Mathias, Michael T. McManus, Terrence F. Meehan, Christian von Mering, Daniel Muthas, Dac-Trung Nguyen, John P. Overington, George Papadatos, Jun Qin, Christian Reich, Bryan L. Roth, Stephan C. Schürer, Anton Simeonov, Larry A. Sklar, Noel ...
Source: Nature Reviews Drug Discovery - March 23, 2018 Category: Drugs & Pharmacology Authors: Tudor I. Oprea Cristian G. Bologa S ø ren Brunak Allen Campbell Gregory N. Gan Anna Gaulton Shawn M. Gomez Rajarshi Guha Anne Hersey Jayme Holmes Ajit Jadhav Lars Juhl Jensen Gary L. Johnson Anneli Karlson Andrew R. Leach Avi Ma'ayan Anna Malovannaya Sub Tags: Analysis Source Type: research
Kinase inhibitors: the road ahead
Nature Reviews Drug Discovery 17, 353 (2018).
doi:10.1038/nrd.2018.21
Authors: Fleur M. Ferguson & Nathanael S. Gray
Receptor tyrosine kinase signalling pathways have been successfully targeted to inhibit proliferation and angiogenesis for cancer therapy. However, kinase deregulation has been firmly demonstrated to play an essential role in virtually all major disease areas. Kinase inhibitor drug discovery programmes have recently broadened their focus (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - March 16, 2018 Category: Drugs & Pharmacology Authors: Fleur M. Ferguson Nathanael S. Gray Tags: Review Source Type: research
